The Use of INGREZZA (valbenazine) Capsules in Patients Taking Monoamine Oxidase Inhibitors (MAOIs)

Thank you for contacting Neurocrine Biosciences with your unsolicited Medical Information request regarding the use of INGREZZA (valbenazine) capsules in patients taking monoamine oxidase inhibitors (MAOIs).

INGREZZA is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with tardive dyskinesia.

The INGREZZA Full Prescribing Information states the following:

Clinical Implication: Concomitant use of INGREZZA with MAOIs may increase the concentration of monoamine neurotransmitters in synapses, potentially leading to increased risk of adverse reactions such as serotonin syndrome, or attenuated treatment effect of INGREZZA.

Prevention or Management: Avoid concomitant use of INGREZZA with MAOIs.

This letter and the enclosed material are provided in response to your unsolicited medical information inquiry. Please feel free to contact Neurocrine Medical Information at (877) 641-3461 or medinfo@neurocrine.com if you would like to request additional information.

Enclosures:

1. INGREZZA [package insert]. Neurocrine Biosciences, Inc., San Diego, CA; 2017.
2. Important Safety Information. Neurocrine Biosciences, Inc., San Diego, CA; 2017.

 

MED-MI-TD-US-0070

Need to get in touch with us?

medinfo@neurocrine.com
1-877-641-3461